ArticleInternational journal of clinical and experimental pathology2017
SOX7 expression correlates with better prognosis in pancreatic cancer patients and is negatively related to pancreatic cancer associated diabetes.
Article in International journal of clinical and experimental pathology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed, 1 citations in OpenAlex.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pancreatic cancer carries a dismal prognosis with a 5-year survival rate of about 5%, and researches have shown that the malignant level and tumor associated glucose metabolism abnormality may both influence the pancreatic cancer progression and prognosis. Recently, growing evidence suggest an association of SOX7 with tumor development. However, there are no studies focusing on the prognostic effect of SOX7 in pancreatic cancer, or its relationship with pancreatic cancer associated diabetes. To investigate the association of SOX7 and prognosis in pancreatic cancer, and further to verify whether SOX7 involves in the regulation of pancreatic cancer associated diabetes. 100 pancreatic cancer-related cases with follow-up information were made into tissue microarrays. Subsequently, the relationship between SOX7 and clinicopathological characteristics was analyzed. SOX7 expression level has a positive correlation with the prognosis of pancreatic cancer patients, especially in the subgroup of tumor size < 5 cm with pathological grades I-II (P=0.014). Moreover, the results showed that SOX7 is significantly negative with diabetes history in the same subgroup (r
Indexed as
Identifiers
31966461PMC6965863W3028147324What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.